<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205231</url>
  </required_header>
  <id_info>
    <org_study_id>2001-557</org_study_id>
    <nct_id>NCT00205231</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease</brief_title>
  <official_title>A Pilot Study to Examine the Feasibility and Effect on Tumor Necrosis Factor (TNF) Inhibition on HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      This pilot study will investigate the safety and effect of etanercept in HIV infection by&#xD;
      studying HIV replication and immune function (as measured by CD4 counts) in individuals with&#xD;
      HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">May 1, 2004</completion_date>
  <primary_completion_date type="Actual">May 1, 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in CD4 counts</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in HIV-RNA levels</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>development of infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degree of TNF inhibition by measuring TNF levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in hematologic and biochemical laboratory tests</measure>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults greater than 18 years of age with documented HIV infection&#xD;
&#xD;
          -  Highly active antiretroviral therapy (HAART) regimens as defined by the Department of&#xD;
             Health and Human Services guidelines; stable regimens for 12 weeks.&#xD;
&#xD;
          -  CD4 greater than 200 at time of study enrollment&#xD;
&#xD;
          -  Stable monitoring labs (hematology survey with differential, ALT, creatinine)&#xD;
&#xD;
          -  Absolute neutrophil count within normal limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AIDS defining illness within the last 6 months&#xD;
&#xD;
          -  Acute bacterial, viral, or fungal infection within the last 1 month, or history of&#xD;
             recurring infections&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Hypersensitivity to etanercept&#xD;
&#xD;
          -  Previous use of etanercept&#xD;
&#xD;
          -  Acute malignancy in the last 5 years excluding in situ cervical cancer (CA) and common&#xD;
             skin cancers (non melanoma)&#xD;
&#xD;
          -  History of active or latent tuberculosis&#xD;
&#xD;
          -  History of demyelinating nerve disease&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  Latex allergy&#xD;
&#xD;
          -  Subject has any of the following laboratory values within 30 days of baseline:&#xD;
&#xD;
               -  hemoglobin concentration &lt; 10.0 g/dl for men and &lt; 9.0 g/dl for women&#xD;
&#xD;
               -  platelet count &lt; 75,000/mm3&#xD;
&#xD;
               -  AST or ALT &gt; 5x upper limit of normal (ULN)&#xD;
&#xD;
               -  serum creatinine &gt; 2.5x ULN&#xD;
&#xD;
               -  serum pancreatic amylase &gt; 1.5 ULN&#xD;
&#xD;
          -  Subject requiring treatment with immunomodulating agents, such as systemic&#xD;
             corticosteroids, interleukins, vaccines, or interferon&#xD;
&#xD;
          -  Subjects who chronically use any over-the-counter (OTC) or prescription medication&#xD;
             (except vitamins) must not change the regimen or switch their medication within 3 days&#xD;
             of drug administration and until discharged from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

